Our ESG Approach
Nxera Pharma has worked hard to lay the foundations of our ESG commitment and to build a clear roadmap to achieving our ESG goals.
In October 2022, Nxera Pharma worked to build our ESG roadmap and identify potential key priority issues (Materiality) and corresponding key performance indicators (KPIs).
The Materiality and KPIs identified were approved by our Board of Directors in March 2023. As Nxera’s ESG long journey roadmap, the Materiality and KPIs set out below are our ESG priority issues and goals that our organization will strive to achieve in the coming years. The objective of our Board of Directors is to implement these ESG goals across our organization and to collaborate with both internal and external stakeholders to ensure these priorities become the foundation of our culture, value and business operations. We recognize that our Materiality and KPIs are long-term objectives that we hope will shape our organization’s values and we look forward to reporting progress through annual ESG reports
CEO Message
Dear Stakeholders
At Nxera Pharma, our commitment to a sustainable and responsible future continues to guide how we operate, innovate, and grow. We believe that advancing science and delivering breakthrough medicines for patients in need must go hand in hand with meaningful progress across environmental, social, and governance (ESG) priorities.Since we identified the Materiality and KPIs in 2022, we’ve made strong progress in embedding ESG principles into our operations, decision-making, and culture. I am pleased to share with you our 2024 ESG Report, which details the steps we’ve taken over the past year to strengthen our impact and contribute positively to society and the planet.
This year, we continued to advance across our ESG KPIs, while scaling our organization and deepening our efforts to operate responsibly and sustainably. From our R&D efforts and development pipeline to our emerging commercial operations, we are building a company designed to deliver value for patients and partners in a way that supports long-term health – both human and environmental.
While I am proud of the progress we have made, we know there is more to do. ESG is a journey, and we remain committed to continuous improvement as we grow and evolve as a company.
Thank you for your continued trust and support.
Chris Cargill
President & CEO
Nxera Pharma